ARS Pharmaceuticals, Inc. (SPRY): Revenue
$84.28M
Year ended 2025-12-31
$116.93M
Trailing 12 months to 2026-06-30
n/m
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $84.28M | -5.5% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $89.15M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $30.0K | -97.7% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $1.32M | -76.1% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $5.51M | n/a | 2023-03-23, From 2021-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $84.28M | -5.5% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $83.98M | +54.0% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $85.33M | -6.2% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $81.36M | +14.9% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $88.04M | +376.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
Compare SPRY, NRIX, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗